News

Cordex Pharma has announced that FDA has approved the design of Phase 2b/3 clinical trials evaluating its lead product ATPace as an antiarrhytmic drug for the treatment of

Schering Plough has announced that the European Medicines Agency (EMEA) has validated the marketing authorization application (MAA) for Sycrest (asenapine) sublingual tablets for the treatment of schizophrenia and

Pfizer has discontinued the SUN 1094 phase III trial of Sutent (sunitinib malate) plus paclitaxel vs. bevacizumab plus paclitaxel, for the first line treatment of patients with advanced

The Chinese market is growing rapidly, and demand for Luminex’s multiplexing technologies among scientists in China is strong, said Patrick J. Balthrop, president and chief executive officer of

Pfizer has announced the launch of Toviaz (fesoterodine fumarate), an extended release tablets and YourWay plan, a customizable support plan for overactive bladder patients, which are now available

The AmerisourceBergen has purchased Innomar Strategies, a Canadian specialty pharmaceutical services company, for approximately C$15 million ($13.8 million) in cash, subject to a working capital adjustment. David Yost,

Concert Pharmaceuticals and GlaxoSmithKline have formed an alliance to develop and commercialize deuterium-containing medicines. The deal includes three of Concert’s research and development programs, CTP-518, a protease inhibitor

Cerus, and a subsidiary of Grifols have announced that the two companies have entered into an agreement to collaborate on the development of red blood cell treatment sets

NeurogesX has declared that the Office of Orphan Product Development (OOPD) of the FDA has granted orphan drug designation for Qutenza (formerly NGX-4010), a high concentration capsaicin dermal